Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VNRX Volitionrx Ltd
- Stocks
- Healthcare
- NYSEAMERICAN: VNRX
Price (delayed)
$0.6358
Market cap
$65.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$70.27M
Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to
Highlights
The gross profit has soared by 64% YoY and by 6% QoQ
The revenue has surged by 64% year-on-year and by 6% since the previous quarter
The equity has dropped by 78% year-on-year and by 12% since the previous quarter
VNRX's debt is up by 33% YoY and by 27% QoQ
Key stats
What are the main financial stats of VNRX
Market
Valuations
Earnings
Shares outstanding
103.02M
Market cap
$65.5M
Enterprise value
$70.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
46.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.71
Revenue
$1.31M
Gross profit
$1.31M
Operating income
-$24.16M
Net income
-$24.02M
EBIT
-$23.66M
EBITDA
-$22.34M
Free cash flow
-$22.1M
Per share
Balance sheet
Liquidity
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.23
Book value per share
-$0.29
Revenue per share
$0.01
TBVPS
$0.08
Total assets
$8.52M
Total liabilities
$37.55M
Debt
$7.37M
Equity
-$27.77M
Working capital
-$4.98M
Debt to equity
-0.27
Current ratio
0.4
Quick ratio
0.34
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
-1,707.4%
Gross margin
100%
Net margin
-1,836.2%
Operating margin
-1,846.8%
Return on assets
-220.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-9,582.4%
Return on sales
-1,808.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNRX stock price
How has the Volitionrx stock price performed over time
Intraday
6.68%
1 week
14.77%
1 month
35.91%
1 year
-5.81%
YTD
5.97%
QTD
11.52%
Financial performance
How have Volitionrx's revenue and profit performed over time
Revenue
$1.31M
Gross profit
$1.31M
Operating income
-$24.16M
Net income
-$24.02M
Gross margin
100%
Net margin
-1,836.2%
The gross profit has soared by 64% YoY and by 6% QoQ
The revenue has surged by 64% year-on-year and by 6% since the previous quarter
The company's operating margin has surged by 58% YoY and by 16% QoQ
VNRX's net margin has soared by 58% YoY and by 16% QoQ
Price vs fundamentals
How does VNRX's price correlate with its fundamentals
Growth
What is Volitionrx's growth rate over time
Valuation
What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
46.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.71
The company's EPS rose by 41% YoY and by 13% QoQ
The equity has dropped by 78% year-on-year and by 12% since the previous quarter
The stock's P/S is 98% below its 5-year quarterly average of 2973.5 but 6% above its last 4 quarters average of 44.1
The revenue has surged by 64% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Volitionrx business performance
The company's return on sales has surged by 58% YoY and by 16% QoQ
Volitionrx's ROA has decreased by 47% YoY and by 11% from the previous quarter
Dividends
What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNRX.
Financial health
How did Volitionrx financials performed over time
The company's total assets is 77% lower than its total liabilities
The company's total assets has shrunk by 56% YoY and by 9% QoQ
VNRX's current ratio is down by 23% since the previous quarter and by 7% year-on-year
VNRX's debt is 127% higher than its equity
The equity has dropped by 78% year-on-year and by 12% since the previous quarter
VNRX's debt is up by 33% YoY and by 27% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.